Local and regional recurrences of localised kidney cancer after nephrectomy

In this study 15 years of data from a single hospital were assessed to look at the outcomes of people who had had surgery for localised renal cell carcinoma (RCC). Of the 1895 people who were assessed, 30 (1.6%) had a single local recurrence of their cancer without distant spread (metastases). In total, 26 of […]

read more

Percutaneous microwave ablation of small renal masses

Percutaneous microwave ablation uses thin needle-like electrodes that are passed through the skin (percutaneous) into the tumour to kill the cancer cells with microwaves. This is usually done under the guidance of ultrasound imaging. During this observational study the short- and long-term outcomes of 113 patients who had microwave ablation for small renal masses (stage […]

read more

Risk of blood clots in cancer patients receiving immunotherapy

A recent study published in Blood has suggested that cancer patients who are being treated with immunotherapy, in particular immune checkpoint inhibitors are at high risk for blood clots (thromboembolism), especially blood clots in veins (venous thromboembolism). Although, the study does not show a causal link between immune checkpoint inhibitor therapy and blood clots. The […]

read more

Role of nephrectomy for metastatic kidney cancer in the immunotherapy era

Three phase III clinical trials (Keynote 426, Checkmate 9ER and Checkmate 214) assessing first-line treatment with immunotherapy in metastatic renal cell carcinoma (RCC) compared to sunitinib were analysed for patients who had prior nephrectomy compared to those who did not. Patients who had prior nephrectomy had a longer time before the immunotherapy stopped working and […]

read more

EIKCS 2021: Future treatments for metastatic kidney cancer

Despite the advances in first-line treatments for metastatic renal cell carcinoma (RCC) over the past few years, new treatments are on the horizon. In a presentation at the European International Kidney Cancer (EIKC) 2021 Virtual Annual Meeting, Dr Hans Hammers from University of Texas Southwestern Medical Center in the USA discussed future treatments for metastatic […]

read more

EIKCS 2021: Biomarkers for kidney cancer

Dr Thomas Powles from St Barts Hospital, London spoke about the work looking for tissue-based biomarkers for renal cell carcinoma (RCC) for potential use in the clinic at the European International Kidney Cancer Symposium (EIKC) 2021 Virtual Meeting. To date, the only biomarker that is used is one to predict survival (prognosis) based on the […]

read more

EIKCS 2021: Second-line and later treatments for metastatic kidney cancer

The increase in the number of first-line treatments for metastatic renal cell carcinoma (RCC) over the past 3 years has had meaningful effects on the choice of second-line treatments. Dr Camillo Porta from the University of Pavia in Italy discussed the selection of second-line and later treatments in a presentation at the European International Kidney […]

read more

EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?

The use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has increased significantly over the past 3 years. However, there are now a number of potential first-line treatments, and choosing the most suitable treatment for each individual patient can be difficult. In a presentation at the European International Kidney Cancer […]

read more

Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer

There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]

read more

Potential role for routine brain imaging in advanced kidney cancer

A recent study published in Journal of the National Comprehensive Cancer Network suggests that brain scans should be considered in most patients with metastatic kidney cancer. 1,689 people with metastatic renal cell carcinoma (RCC) had MRI brain scans for entry into clinical trials. Of these, 4% had brain metastases that did not show any symptoms. […]

read more
Showing 1 to 10 of 769 results
  TOP